Trial Profile
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Dec 2023
Price :
$35
*
At a glance
- Drugs Ciforadenant (Primary) ; Mupadolimab (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Triple negative breast cancer; Uterine cancer
- Focus Adverse reactions
- Sponsors Corvus Pharmaceuticals
- 19 Dec 2023 Status changed from active, no longer recruiting to completed.
- 08 May 2023 According to Corvus media release, data from this study is expected to be released before end of 2023.
- 01 Aug 2022 Status changed from recruiting to active, no longer recruiting.